Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Compugen Ltd.’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
65
5 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
Compugen Ltd. its own name
named as the applicant on its applications, in IL. 2 more under the same name are not counted (printed in CH, printed in DE)
65 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 18, 2025 | 2025/0382364 | ANTI-TIGIT AND ANTI-PVRIG IN MONOTHERAPY AND COMBINATION TREATMENTS | Pharmaceuticals | Compugen Ltd. |
| Nov 6, 2025 | 2025/0339522 | COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS, ANTI-TIGIT ANTIBODIES, AND ANTI-PD-1 ANTIBODIES | Pharmaceuticals | Compugen Ltd. |
| Oct 30, 2025 | 2025/0333503 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | Pharmaceuticals | Compugen Ltd. |
| Sep 25, 2025 | 2025/0297018 | IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER | Pharmaceuticals | Compugen Ltd. |
| May 1, 2025 | 2025/0136710 | TRIPLE COMBINATION ANTIBODY THERAPIES | Biotechnology | Compugen Ltd. |
| Dec 26, 2024 | 2024/0425607 | IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER | Pharmaceuticals | Compugen Ltd. |
| Aug 29, 2024 | 2024/0287174 | HIDE1 COMPOSITIONS AND METHODS | Pharmaceuticals | Compugen Ltd. |
| May 2, 2024 | 2024/0139318 | ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF | Pharmaceuticals | Compugen Ltd. |
| Mar 28, 2024 | 2024/0103010 | PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT | Analysis of biological materials | Compugen Ltd. |
| Mar 28, 2024 | 2024/0101669 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | Pharmaceuticals | Compugen Ltd. · patent 12,312,404 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Biotechnology 2 · Analysis of biological materials 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.